Too many unknowns to give a meaningful answer. It would depend on the ratio of the new shares to the old shares and what news has been announced between now and the reverse split announcement.
I'm waiting to see the "final" LymPro data and also to see how Gerald finances the ESS acquisition before making a buying decision.
The company's operating loss was over $4.5M for the third quarter and I expect it will continue to increase substantially over the next 12-18 months.
Currently the only "known" source of funds is through Gerald selling more shares either to L.P.C. or some other investment group such as International Infusion.
Without another source of funding the dilution will only increase.
News 
Market Data 
Discover 
